PHAXIAM Therapeutics S.A. (0QSS.L)
| Chiusura precedente | 5,0000 |
| Aperto | 4,9000 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 4,8500 - 4,9995 |
| Intervallo di 52 settimane | 3,5996 - 11,4000 |
| Volume | |
| Media Volume | 566 |
| Capitalizzazione | 75,227M |
| Beta (5 anni mensile) | 1,94 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,7330 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswirePhaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM
Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM Lyon (France) and Cambridge (MA, US), June 28, 2023 - Phaxiam Therapeutics (Nasdaq & Euronext: FR0011471135), announces change of the mnemonic code of its share from ERYP to PHXM, following the merger between ERYTECH and PHERECYDES. The change has been notified by Euronext and will be effective from June 29, 2023. Company name: Phaxiam TherapeuticsISIN code: FR0011471135Mnemonic: PHXMListing: Euronext Paris (Compar
- GlobeNewswire
Monthly information related to total number of voting rights and shares composing the share capital - June 26, 2023
Monthly information related to total number of voting rights and shares composing the share capital _June 26, 2023. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2)
- GlobeNewswire
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics
ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics Merger approved with large majority by the shareholders of both companiesNew governance structure implementedAmbition to create a global leader in extended phage therapies to target antimicrobial resistant pathogenic bacteria Lyon (France) and Cambridge (MA, US), June 26, 2023 – ERYTECH (Nasdaq & Euronext: ERYP) and PHERECYDES announce merger and name change to PHAXIAM Therapeutics, a clinical-stage biopharmaceutical
